MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

开始日期2025-01-15

申办/合作机构

Mayo Clinic

NCT05477446

/ Not yet recruiting临床1期IIT

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With Relapsed and Refractory (R/R) Langerhans Cell Histiocytosis

This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis.

开始日期2022-10-01

申办/合作机构

北京友谊医院

[+1]

ChiCTR2200060467

/ Suspended临床1期IIT

Clinical study of the safety and efficacy of chimeric antigen receptor gene-modified T cells targeting CD207 in the treatment of relapsed/refractory Langerhans histiocytosis

开始日期2022-06-01

申办/合作机构-

100 项与难治性朗格汉斯细胞组织细胞增生症相关的临床结果

登录后查看更多信息

100 项与难治性朗格汉斯细胞组织细胞增生症相关的转化医学

登录后查看更多信息

0 项与难治性朗格汉斯细胞组织细胞增生症相关的专利（医药）

登录后查看更多信息

项与难治性朗格汉斯细胞组织细胞增生症相关的文献（医药）

2024-05-01·British Journal of Haematology

From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies

Article

作者: Diamond, Akiva

The treatment landscape for relapsed Langerhans cell histiocytosis (LCH) is fraught with uncertainty due to a scarcity of data. Karri et al.'s study provides promising evidence that combining MAPK pathway inhibitors with chemotherapy could improve outcomes, even for patients with multiple relapses. Although larger studies are needed, this approach suggests a shift towards more aggressive, potentially curative strategies in the management of LCH.Commentary on: Karri et al. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol 2024;204:1882‐1887.

2024-05-01·British Journal of Haematology

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis

Article

作者: Batajoo, Akanksha ; Eckstein, Olive ; Velazquez, Jessica ; Lin, Howard ; Saha, Anikit ; Karri, Vivekanudeep ; Woods‐Swafford, Wendy ; Agrusa, Jennifer ; Boyd, Jaime ; Allen, Carl E. ; McClain, Kenneth L. ; Parekh, Deevyashali ; Stanton, Whitney ; Gulati, Nitya ; Schwartz, Jeffrey ; Abhyankar, Harshal ; El‐Mallawany, Nader K.

SummaryOptimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients with refractory systemic disease and/or LCH‐associated neurodegeneration. Overall response rate was 9/10 (90%) for the entire cohort: 5/5 (100%) for patients with systemic disease and 6/7 (86%) for patients with central nervous system disease. BRAFV600E+ peripheral blood fraction decreased in 5/6 (83%). Toxicities included fever, skin rash, myalgias, neuropathy, cytopenias and hypocalcaemia. Prospective trials are required to optimize combination strategies, determine potential to achieve cure and compare outcomes to chemotherapy or MAPK inhibitor monotherapy.

2024-05-01·Asian Pacific Journal of Cancer Prevention

Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis

Article

作者: Komvilaisak, Patcharee ; Sathitsamitphong, Lalita ; Sanpakit, Kleebsabai ; Chainansamit, Su-On ; Seksarn, Panya ; Traivaree, Chanchai ; Suwannaying, Kunanya ; Buaboonnam, Jassada ; Monsereenusorn, Chalinee ; Pakakasama, Samart ; Techavichit, Piti ; Anurathapan, Usanarat ; Charoenkwan, Pimlak

BACKGROUNDDisease reactivation/refractory remains a major challenge in managing Langerhans cell histiocytosis (LCH). Outcomes and late sequelae should be explored.METHODSA multi-institutional retrospective study was conducted to describe clinical characteristics, predictive factors, outcomes and late sequelae of pediatric reactivation/refractory LCH in Thailand.RESULTSIn all, 47 patients were studied, 25 (53.2%) patients had disease reactivation and 22 (46.8%) patients had refractory LCH. The median reactivation and refractory time were 1.59 and 0.33 years from diagnosis, respectively (p <0.001). The most common site of reactivation/refractory was the bone (n = 26, 55%), and 20 (42.6%) patients developed late sequelae. The 5-year overall survival (OS) was 76.1%. Patients with reactivation and refractory LCH performed similarly in 5-year OS (88% vs. 63%, p = 0.055). Prognostic factors associated with mortality were liver, spleen, hematopoietic system and lung reactivation (p <0.05). Lung reactivation was the only independent risk factor associated with the survival outcome (p = 0.002).CONCLUSIONSThe outcomes of pediatric patients between reactivation and refractory LCH in Thailand were similarly desirable and mortality was minimal although late sequelae may evolve. Pulmonary reactivation/refractory was an independent risk factor associated with survival.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。